Roberta Lipson is the founder of United Family Healthcare (UFH) and the V. Chair of New Frontier Health. She has over 40 years of experience as a pioneer in the healthcare industry in China. She originally co-founded United Family Healthcare’s predecessor company Chindex in 1981, expanding the business from China’s top medical equipment distribution company into China’s first and largest foreign-invested healthcare system. After over two decades, UFH’s healthcare platform inludes 11 hospitals and almost 20 clinics in Beijing, Shanghai, Guangzhou, Tianjin, Qingdao, Hainan and Shenzhen, as well as an internet hospital serving patients nationally. The company has become the provider of choice for those seeking premium, personalized healthcare. United Family Healthcare was rated in 2016 as “The Most Trusted Healthcare Brand of China” by the Chinese Business Journal, and has appeared at the top of private hospital listings every year since .

As founder and CEO Ms. Lipson took her company public on NASDQ in 1994, and then again merged with a NYSE:NFH in 2019, and in 2021 was again part of the buying consortium to again privatize the company .

Ms. Lipson is an active leader in the business community in Beijing, currently serving for the ninth year as a director and audit committee chair of the U.S. China Business Council, enters her seventh term on the AmCham China Board as the Vice Chair, and as Co-Chair of the AmCham Healthcare Forum and founding Chair of the Healthcare China Program (HCP) . She also chairs the Board of the United Foundation for China’s Health (UFCH), and is a co- founder of Beijing’s Jewish Community - Kehillat Beijing. Because of her outstanding contribution in China, Roberta Lipson received “The Great Wall Friendship Award” in 2009, the highest honor that Beijing government gives to foreign experts in Beijing. In 2014 Roberta was honored by AmCham as the inaugural recipient of the China Pioneer Award. She was named as a “Top 10 Business Leader of China” by Sina.com in 2015, the Brandeis University Asper Award for Entrepeneurship and earlier she led the company to win the U.S. State Department ACE Award for Corporate Excellence. She has lived and worked in Beijing for over 40 years, and in 2017 Ms. Lipson received Foreign Permanent Resident Card. Ms. Lipson holds a BA from Brandeis University and an MBA from Columbia University.

Richard is a Partner at Sinovation Disrupt Fund, a $500 million technology fund focusing on growth investments. Previously, he was with Sinovation's venture funds as an advisor and then a Partner from 2015 to 2021. He has 18 years of experience in technology entrepreneurship and investments.

Richard focuses on the technologies and services in health and productivity sectors worldwide. He manages an active portfolio of 30+ companies such as Meditrust 镁信健康, Insilico Medicine 英矽智能, XAG 极飞, Megarobo 镁伽, and Glinx 基灵.

Richard graduated from Washington University in St. Louis with a Bachelor of Science in Business Administration.

Over 18 years dedicated in government affairs and public policy across several industries and over decade years focus on Pharma industry, with in-depth understanding of China government institution and policy. She brings to the companies she serves an in-depth knowledge of the Chinese political and regulatory environments and policy-making process. Additionally, she has extensive network with senior government officials at both central and local levels. In all her roles, she has demonstrated strong commitment and robust government partnership to shape innovation system for industry’s development in China, maximizing access as well as outcomes so that patient can truly benefit.

She is now the Head of Government Affairs in Bristol-Myers Squibb, China, where she is responsible for building BMS Government affairs organization in China, formulating GA, Policy and advocacy strategies in China, to implement BMS China 2030 strategy by partnership with Government, as well as shaping the political and legislative environments with a view of maximizing business opportunities in China.

Before Michelle joined BMS, she had been servicing in Novartis Group China as Senior Director for 9 years, where she held multiple government affairs positions between 2012 and 2021. responsible for building a reputation of impeccable integrity for Novartis by directing a long-term Government affairs strategy in China.

Before entering pharmaceutical industry, Michelle was Head of Government affairs and BD of Seiko Epson Group (China), and over the course of her career, she has held a number of senior government affairs roles in MNC companies, including 7 years in FMCG industry. She has demonstrated leadership to lead complex, cross-departmental projects. Strong Cross-BU Leadership and communication skills, especially in an MNC with matrix structure Before Michelle starting her career in MNC, she worked in Dalian Municipal government.

Michelle is also very active in industry activities, she is:
Vice-Chair, Healthcare and Pharmaceutical Committee, European Chamber of Commerce China (EUCCC)
Vice-Chair, Biomedicine Committee, CIPA;
Guest Lecturer, School of international Relations, Beijing Foreign Studies University.

Michelle got Law degree at Liaoning University and Public Relation at GuangHua Management School, Peking University.

Yuan Li leads EIU CS China office. He work closely with various pharmaceutical and medical device multinational key clients in Greater China region for more than 7 years.

Yuan has rich experience in delivering speech and is also panel moderator healthcare events. In the past few years, he has hosted and presented in several healthcare events, on a broad range of topics megatrends impacting healthcare delivery, regulatory policies, competitive landscape, and clinical & technology transforming the patient care.

Mattie Bekink is responsible for the Economist Intelligence Corporate Network’s China strategy, including programme development and client engagement across China.

Ms Bekink has extensive experience in the public, private and policy sectors. Prior to joining The Economist Group, she was the Executive Director of the Fulbright Commission in the Netherlands. She also ran an eponymous consulting business, advising businesses, universities and non-profit organisations on China policy, strategy, public affairs, and CSR. Ms Bekink practiced law at Skadden, Arps, Slate, Meagher & Flom LLP, has worked with the US-Asia Law Initiative at NYU Law School and the American Bar Association Rule of Law Initiative China Program, and served in the legal department at General Motors China.

Ms Bekink has a BA in International Relations from Stanford University and a JD from the Georgetown University Law Center.

Robert Xiao is the Director of the Economist Intelligence Corporate Network (EICN) in Beijing. He is responsible for engaging with top executives in the region and providing insights on economic and policy trends to support their business development in the Chinese market.

Mr Xiao was previously a PhD Supervisor and Deputy Director of the Impact Finance Hub at Deakin Business School before joining EICN. His research mainly focused on the fields of corporate social responsibility, corporate governance, and economic and financial policy analysis related to the Chinese market. He has authored multiple publications in Financial Times Top 50 Journals and been awarded major research grants jointly by the Australia Academy of Social Sciences and Chinese Academy of Social Sciences. He also has more than a decade of experience teaching business courses including in Master of Business Administration (MBA), Master of Finance, and Bachelor of Commerce programmes at leading universities.

Mr Xiao has a Ph.D. in Finance and B.Com. (Hons) in Accounting and Finance from Monash University.